Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose apatinib for newly diagnosed or recurrent high-grade glioma
ChiCTR1800015764Phase 4Recruiting
- Sponsor
- Gansu Cancer Hospital
- Start
- Apr 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in glioma, sponsored by Gansu Cancer Hospital. Primary endpoints: Intracranial progression-free survival, Progression-free survival and 1 more. Started Apr 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR1800015764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015764.